AF |
Atrial Fibrillation |
ANP/NT-proANP |
Atrial natriuretic peptide/N-terminal-proANP |
ASCVD |
Atherosclerotic cardiovascular disease |
BNP/NT-proBNP |
Brain/B-type natriuretic peptide/N-terminal-proBNP |
CKD |
Chronic kidney disease |
CSS |
Clinical summary score |
CV |
Cardiovascular |
EF |
Ejection fraction |
eGFR |
Estimated glomerular filtration rate |
ESRD |
End-stage renal disease |
HF |
Heart failure |
HFrEF |
Heart failure with reduced ejection fraction |
HFpEF |
Heart failure with preserved ejection fraction |
HHF |
Hospitalization due to heart failure |
HR |
Hazard ratio |
KCCQ |
Kansas City Cardiomyopathy Questionnaire |
LVEF |
Left ventricular ejection fraction |
MACE |
Major adverse cardiac events |
NO |
Nitric oxide |
NPs |
Natriuretic peptides |
NYHA |
New York Heart Association |
OMT |
Optimal medical therapy |
RAAS |
Renin-angiotensin-aldosterone system |
SGLT-2i |
Sodium-glucose cotransporter-2 inhibitors |
SNS |
Sympathetic nervous system |
T2DM/T1DM |
Type 2/Type 1 diabetes mellitus |